Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8487)
All Articles published online
|
Publishing Process of This Article
|
Sep 28, 2015 (publication date) through Jan 3, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol 2015; 21(36): 10336-10347 [PMID: 26420960 DOI: 10.3748/wjg.v21.i36.10336] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i36/10336.htm |
| Number | Citing Articles |
| 1 |
Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Takuro Hisanaga, Takuya Iwamoto, Koichi Fujisawa, Toshihiko Matsumoto, Isao Hidaka, Yoshio Marumoto, Tsuyoshi Ishikawa, Naoki Yamamoto, Yutaka Suehiro, Taro Takami, Isao Sakaida. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib <i>vs</i> hepatic arterial infusion chemotherapy. World Journal of Hepatology 2018; 10(9): 571-584 doi: 10.4254/wjh.v10.i9.571
|
| 2 |
Antonella Cammarota, Valentina Zanuso, Giulia Francesca Manfredi, Ravindhi Murphy, David James Pinato, Lorenza Rimassa. Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?. Therapeutic Advances in Medical Oncology 2023; 15 doi: 10.1177/17588359221148029
|
| 3 |
Ashly Hindle, Chhanda Bose, Jihyun Lee, Philip T. Palade, Christopher J. Peterson, P. Hemachandra Reddy, Sanjay Awasthi, Sharda P. Singh. Rlip Depletion Alters Oncogene Transcription at Multiple Distinct Regulatory Levels. Cancers 2022; 14(3): 527 doi: 10.3390/cancers14030527
|
| 4 |
Nahla E. El-Ashmawy, Eman G. Khedr, Hoda A. El-Bahrawy, Eslam E. Abd El-Fattah. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clinical and Experimental Medicine 2017; 17(2): 185 doi: 10.1007/s10238-016-0416-3
|
| 5 |
Sandrine Faivre, Armando Santoro, Robin K. Kelley, Ed Gane, Charlotte E. Costentin, Ivelina Gueorguieva, Claire Smith, Ann Cleverly, Michael M. Lahn, Eric Raymond, Karim A. Benhadji, Gianluigi Giannelli. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver International 2019; 39(8): 1468 doi: 10.1111/liv.14113
|
| 6 |
Georgi Atanasov, Karoline Dino, Katrin Schierle, Corinna Dietel, Gabriela Aust, Johann Pratschke, Daniel Seehofer, Moritz Schmelzle, Hans-Michael Hau. Angiogenic inflammation and formation of necrosis in the tumor microenvironment influence patient survival after radical surgery for de novo hepatocellular carcinoma in non-cirrhosis. World Journal of Surgical Oncology 2019; 17(1) doi: 10.1186/s12957-019-1756-8
|
| 7 |
Satoshi Narahara, Takehisa Watanabe, Katsuya Nagaoka, Nahoko Fujimoto, Yoki Furuta, Kentaro Tanaka, Takayuki Tokunaga, Takeshi Kawasaki, Yoko Yoshimaru, Hiroko Setoyama, Kentaro Oniki, Junji Saruwatari, Masakuni Tateyama, Hideaki Naoe, Motohiko Tanaka, Yasuhito Tanaka, Yutaka Sasaki. Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma. Hepatology Communications 2022; 6(5): 1198 doi: 10.1002/hep4.1872
|
| 8 |
Yu-Yun Shao. Another prognostic marker for hepatocellular carcinoma. Hepatology International 2023; 17(2): 279 doi: 10.1007/s12072-023-10504-1
|
| 9 |
Francesco Tovoli, Stefania De Lorenzo, Maria Aurelia Barbera, Ingrid Garajova, Giorgio Frega, Andrea Palloni, Maria Abbondanza Pantaleo, Guido Biasco, Giovanni Brandi. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. Future Oncology 2017; 13(21): 1893 doi: 10.2217/fon-2017-0166
|
| 10 |
David W. Victor, Howard P. Monsour, Maha Boktour, Keri Lunsford, Julius Balogh, Edward A. Graviss, Duc T. Nguyen, Robert McFadden, Mukul K. Divatia, Kirk Heyne, Victor Ankoma-Sey, Chukwuma Egwim, Joseph Galati, Andrea Duchini, Ashish Saharia, Constance Mobley, A. Osama Gaber, R. Mark Ghobrial. Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience. Transplantation 2020; 104(1): 113 doi: 10.1097/TP.0000000000002835
|
| 11 |
Marwa G. El-Gazzar, Rania M. El-Hazek, Nashwa H. Zaher, Mona A. El-Ghazaly. Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study. Bioorganic Chemistry 2019; 92: 103251 doi: 10.1016/j.bioorg.2019.103251
|
| 12 |
Hiroyuki Suzuki, Hideki Iwamoto, Takahiro Seki, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Yasuko Imamura, Takashi Niizeki, Masahito Nakano, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Miwa Sakai, Kazutoyo Morita, Masamichi Nakayama, Tomoharu Yoshizumi, Ryoko Kuromatsu, Hirohisa Yano, Yihai Cao, Hironori Koga, Takuji Torimura. Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors. Cancer Communications 2023; 43(4): 415 doi: 10.1002/cac2.12411
|
| 13 |
Francesco Tovoli, Giulia Negrini, Francesca Benevento, Chiara Faggiano, Elisabetta Goio, Alessandro Granito. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepatic Oncology 2018; 5(1) doi: 10.2217/hep-2017-0020
|
| 14 |
Eileen L. Yoon, Jong Eun Yeon, Eunjung Ko, Hyun Jung Lee, Ji Hye Je, Yang Jae Yoo, Seong Hee Kang, Sang Jun Suh, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun. An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Journal of Korean Medical Science 2017; 32(2): 212 doi: 10.3346/jkms.2017.32.2.212
|
| 15 |
Maneesha Bhullar, Anisha Bhullar, Niranjan J Arachchi. Painful Rashes on the Palms and Soles. Annals of the Academy of Medicine, Singapore 2016; 45(10): 479 doi: 10.47102/annals-acadmedsg.V45N10p479
|
| 16 |
Yu Wang, Baocheng Deng. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer and Metastasis Reviews 2023; 42(3): 629 doi: 10.1007/s10555-023-10084-4
|
| 17 |
Ayako Iida-Ueno, Masaru Enomoto, Sawako Uchida-Kobayashi, Atsushi Hagihara, Yuga Teranishi, Hideki Fujii, Hiroyasu Morikawa, Yoshiki Murakami, Akihiro Tamori, Le Thi Thanh Thuy, Norifumi Kawada. Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology 2018; 82(5): 857 doi: 10.1007/s00280-018-3681-x
|
| 18 |
Taku Shigesawa, Goki Suda, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Ren Yamada, Takashi Kitagataya, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto. Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. JGH Open 2020; 4(5): 880 doi: 10.1002/jgh3.12339
|
| 19 |
Bang-Bin Chen, Chao-Yu Hsu, Chih-Wei Yu, Po-Chin Liang, Chiun Hsu, Chih-Hung Hsu, Ann-Lii Cheng, Tiffany Ting-Fang Shih. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. European Radiology 2017; 27(7): 3069 doi: 10.1007/s00330-016-4670-2
|
| 20 |
Chiun Hsu, Ann-Lii Cheng. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Resistance to Targeted Anti-Cancer Therapeutics 2017; 13: 93 doi: 10.1007/978-3-319-56197-4_5
|
| 21 |
Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Reo Kawano, Takuro Hisanaga, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. Liver Cancer 2018; 7(4): 359 doi: 10.1159/000487858
|
| 22 |
Marta Campos, Isabel Candelária, Nickolas Papanikolaou, Adélia Simão, Carlos Ferreira, Georgios C. Manikis, Filipe Caseiro-Alves. Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study. GE - Portuguese Journal of Gastroenterology 2019; 26(4): 260 doi: 10.1159/000493351
|
| 23 |
Pil Soo Sung, Hye Lim Park, Keungmo Yang, Seawon Hwang, Myeong Jun Song, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Ie Ryung Yoo, Si Hyun Bae.
18F–fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. European Journal of Nuclear Medicine and Molecular Imaging 2018; 45(3): 384 doi: 10.1007/s00259-017-3871-5
|
| 24 |
Haiyu Wang, Benchen Rao, Jiamin Lou, Jianhao Li, Zhenguo Liu, Ang Li, Guangying Cui, Zhigang Ren, Zujiang Yu. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology 2020; 8 doi: 10.3389/fcell.2020.00055
|
| 25 |
Li Gong, Marilyn M. Giacomini, Craig Giacomini, Michael L. Maitland, Russ B. Altman, Teri E. Klein. PharmGKB summary. Pharmacogenetics and Genomics 2017; 27(6): 240 doi: 10.1097/FPC.0000000000000279
|
| 26 |
Maya König, Alice Nentwig, Eliane Marti, Jelena Mirkovitch, Katja‐Nicole Adamik, Simone Schuller. Evaluation of plasma angiopoietin‐2 and vascular endothelial growth factor in healthy dogs and dogs with systemic inflammatory response syndrome or sepsis. Journal of Veterinary Internal Medicine 2019; 33(2): 569 doi: 10.1111/jvim.15369
|
| 27 |
Lize Deferme, Jarno E. J. Wolters, Sandra M. H. Claessen, Daniel H. J. Theunissen, Twan van den Beucken, J. Richard Wagner, Simone G. van Breda, Jos C. S. Kleinjans, Jacco J. Briedé. Dynamic Interplay between the Transcriptome and Methylome in Response to Oxidative and Alkylating Stress. Chemical Research in Toxicology 2016; 29(9): 1428 doi: 10.1021/acs.chemrestox.6b00090
|
| 28 |
Shaoming Song, Mingzhen Bai, Xiaofei Li, Shiyi Gong, Wenwen Yang, Caining Lei, Hongwei Tian, Moubo Si, Xiangyong Hao, Tiankang Guo. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2022; 22(3): 361 doi: 10.1080/14737159.2022.2049248
|
| 29 |
Jian-jun Li, Jie Luo, Jing-ning Lu, Xiao-na Liang, Yi-huan Luo, Yong-ru Liu, Jie Yang, Hua Ding, Gui-hui Qin, Li-hua Yang, Yi-wu Dang, Hong Yang, Gang Chen. Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study. Cancer Cell International 2016; 16(1) doi: 10.1186/s12935-016-0352-z
|
| 30 |
Lingyu Jiang, Shuyan Liu, Tingzhi Deng, Yang Yang, Yin Zhang. Analysis of the expression, function and signaling of glycogen phosphorylase isoforms in hepatocellular carcinoma. Oncology Letters 2022; 24(2) doi: 10.3892/ol.2022.13364
|
| 31 |
Takuya Adachi, Kazuhiro Nouso, Koji Miyahara, Atsushi Oyama, Nozomu Wada, Chihiro Dohi, Yasuto Takeuchi, Tetsuya Yasunaka, Hideki Onishi, Fusao Ikeda, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Takabatake, Shin‐ichi Fujioka, Haruhiko Kobashi, Yoshitaka Takuma, Shouta Iwadou, Shuji Uematsu, Koichi Takaguchi, Hiroaki Hagihara, Hiroyuki Okada. Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib. Journal of Gastroenterology and Hepatology 2019; 34(6): 1081 doi: 10.1111/jgh.14535
|
| 32 |
Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Jean-Frederic Blanc, Ho Yeong Lim, Albert Tran, Yi-Wah Chan, Paul McAdam, Evelyn Wang, Ann-Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou-Alfa. Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. Liver Cancer 2022; 11(1): 38 doi: 10.1159/000519867
|
| 33 |
Cedric Brackenier, Lisa Kinget, Sarah Cappuyns, Chris Verslype, Benoit Beuselinck, Jeroen Dekervel. Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. Cancers 2023; 15(2): 348 doi: 10.3390/cancers15020348
|
| 34 |
Faryal Mehwish Awan, Anam Naz, Ayesha Obaid, Aqsa Ikram, Amjad Ali, Jamil Ahmad, Abdul Khaliq Naveed, Hussnain Ahmed Janjua. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-11943-1
|
| 35 |
Yu-Yun Shao, Hang Lin, Yong-Shi Li, Ying-Hui Lee, Ho-Min Chen, Ann-Lii Cheng, Chih-Hung Hsu. High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. Japanese Journal of Clinical Oncology 2017; 47(10): 949 doi: 10.1093/jjco/hyx103
|